Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Jefferies Group increased their FY2017 EPS estimates for shares of Alnylam Pharmaceuticals in a report released on Monday, according to Zacks Investment Research. Jefferies Group analyst M. Raycroft now anticipates that the biopharmaceutical company will post earnings per share of ($5.39) for the year, up from their previous forecast of ($5.49). Jefferies Group also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.32) EPS, FY2018 earnings at ($5.70) EPS, FY2019 earnings at ($3.91) EPS, FY2020 earnings at ($1.71) EPS and FY2021 earnings at $1.41 EPS.
A number of other research firms have also commented on ALNY. Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 9th. Cowen reaffirmed a “buy” rating and issued a $151.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 9th. Credit Suisse Group increased their target price on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Leerink Swann increased their target price on shares of Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a “market perform” rating in a research report on Thursday, January 25th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $152.00 target price (up previously from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Alnylam Pharmaceuticals has a consensus rating of “Buy” and an average price target of $123.93.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down $4.93 during trading on Wednesday, reaching $124.50. 787,152 shares of the company were exchanged, compared to its average volume of 932,830. Alnylam Pharmaceuticals has a 1 year low of $39.66 and a 1 year high of $147.63. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. The firm has a market cap of $12,726.96, a price-to-earnings ratio of -23.71 and a beta of 2.69.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm had revenue of $17.10 million during the quarter, compared to analyst estimates of $28.15 million. During the same period in the prior year, the business posted ($1.21) EPS. The company’s revenue for the quarter was up 24.8% on a year-over-year basis.
In related news, CEO John Maraganore sold 74,000 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total value of $9,387,640.00. Following the transaction, the chief executive officer now owns 223,710 shares in the company, valued at approximately $28,379,850.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the transaction, the vice president now owns 6,352 shares in the company, valued at approximately $835,859.68. The disclosure for this sale can be found here. Insiders have sold a total of 220,409 shares of company stock worth $28,667,017 in the last 90 days. 4.30% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Strs Ohio bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth $141,000. CENTRAL TRUST Co raised its holdings in Alnylam Pharmaceuticals by 746.3% in the 4th quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 1,000 shares during the period. Livforsakringsbolaget Skandia Omsesidigt bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth $165,000. QS Investors LLC raised its holdings in Alnylam Pharmaceuticals by 59.7% in the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 900 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 167 shares during the period. Hedge funds and other institutional investors own 88.44% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/03/jefferies-group-weighs-in-on-alnylam-pharmaceuticals-inc-s-fy2017-earnings-alny.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.